Like this? Get a daily dose of D.C.-area funding news in The Beat. Sign up here.
Here are all of the tech funding deals out of the Washington, D.C., area this week. We’ll be updating this post as more news comes out.
Thursday, September 17
TCP Venture Capital / Propel Baltimore Fund II (Baltimore, Md.)
- Deal: raised $4.45M from a $15M equity offering on the total fund, according to an SEC filing
- Investors: undisclosed, associated with Abell Foundation, Maryland Technology Development Corp. (TEDCO), Robert W. Deutsch Foundation, Clayton Baker Trust. Organizers, according to the Baltimore Sun
- What they do: fuel investments in high-growth, early-stage tech companies willing to establish headquarters in Baltimore.
- Other details: investment thesis for fund, according to TCP Venture Capital "the severe undercapitalization of post-Series Seed companies in Baltimore City represents an attractive opportunity for investment."
Wednesday, September 16
HighCape Partners (Baltimore, Md.)
- Deal: raised a new $80M fund (initial growth equity fund)
- Investors: undisclosed
- What they do: private equity firm that invests in commercial-stage life sciences companies
- Other details: The firm is currently two companies in its portfolio: Cheetah Medical, a non-invasive cardiac output and hemodynamic monitoring developer, and TELA Bio, a surgical reconstruction company focused on soft tissue repair.
Monday, September 14
Theranostics Health (Rockville, Md.)
- Deal: $150K equity offering raise, according to an SEC filing
- Investors: undisclosed, previous include: Maryland Venture Fund
- What they do: research services for drug development companies; focused on the quantitative measurement of proteins in diseases."Theranostics Health is pursuing two parallel business lines. One business line focuses upon providing protein-based translational research services to drug development companies and academic institutions for biomarker and companion diagnostic purposes. Our technologies are of particular use for companies that develop molecular targeted therapies or combination therapies as they allow insights into the phospho-activation status of drug targets and receptors, their downstream pathways, and potential survival or adaptive mechanisms within targeted cell populations," the company's website reads.
- Other details: active private investment history includes multiple +$1M raises from a series of private investors since 2011
